Translation of cellular therapies from aGVHD mouse models into clinical trials
| Main conclusion from the mouse model of GVHD . | Reference . | Clinical trial . | Reference . |
|---|---|---|---|
| Treg transfer reduces GVHD (2002, 2003) | 40,42,100 | Treg transfer is associated with low GVHD rates (2011, 2011, 2016). Open label and phase 1 trials | 101,-103 |
| Th2 cells generated by rapamycin exposure cause GVHD protection (2005) | 107 | Rapamycin-resistant donor CD4+ Th2/Th1 transfer after allo-HCT is well-tolerated and connected to low aGVHD day 100 (2013). Phase 2 clinical trial | 108 |
| MSCs reduce GVHD (2012) | 130 | MSC reduces GVHD in open-label studies and phase 2 trials (2004, 2014) | 110,111 |
| Main conclusion from the mouse model of GVHD . | Reference . | Clinical trial . | Reference . |
|---|---|---|---|
| Treg transfer reduces GVHD (2002, 2003) | 40,42,100 | Treg transfer is associated with low GVHD rates (2011, 2011, 2016). Open label and phase 1 trials | 101,-103 |
| Th2 cells generated by rapamycin exposure cause GVHD protection (2005) | 107 | Rapamycin-resistant donor CD4+ Th2/Th1 transfer after allo-HCT is well-tolerated and connected to low aGVHD day 100 (2013). Phase 2 clinical trial | 108 |
| MSCs reduce GVHD (2012) | 130 | MSC reduces GVHD in open-label studies and phase 2 trials (2004, 2014) | 110,111 |